GM-CSF Antikörper

Antigen: GM-CSF

Synonyme: GMCSF, GM-CSF

Klonalität: Monoklonal (BVD2-23B6)

Wirt: Ratte

Reaktivität: Human, Rhesusaffen

Applikation: ELISA (Fangantikörper), ELISPOT (Fangantikörper), Neutralisierung (Neut), Immunpräzipitation (IP), Western Blot (WB)

Produktnummer: ABIN160209

Produktbeschreibung

Immunogen: E. coli -expressed, recombinant human GM-CSF

Format: Low endotoxin (sterile), Low-endotoxin, azide-free (LEAF)

Isotyp: IgG2a, kappa chain  (Passende Sekundärantikörper)

Klon: BVD2-23B6

Beschreibung: Growth/development granulocyte/macrophage progenitors, differentiates myeloblasts/monoblasts, synergizes with Epo proliferation of erythroid/megakaryocytic progenitors T cells, macrophages, fibroblasts, endothelial cells, mast cells Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated T cells, B cells, mast cells, macrophages, fibroblasts and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte and eosinophil progenitors. The BVD2-23B6 antibody reacts with human granulocyte/macrophage - colony stimulating factor (GM-CSF). The BVD2-23B6 antibody can neutralize the bioactivity of natural or recombinant GM-CSF. Synonyms: Granulocyte/macrophage colony-stimulating factor, CSF-alpha, Pluripoietin-alpha, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA) Regulation: Synergistic with IL-1, IL-3, G-CSF, E21R competitive antagonist for receptor binding, stored in ECM with heparan sulfate proteoglycans Structure: Cytokine, 22 kD (Mammalian)

Anwendungen

Applikationshinweise: ELISA or ELISPOT Capture: The purified BVD2-23B6 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD2-21C11 antibody (ABIN160213) as the detecting antibody. The LEAF(TM) purified antibody is suggested for ELISPOT capture. Neutralization: The LEAF(TM) purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm sterile-filtered) is recommended for neutralization of human GM-CSF bioactivity (ABIN160209). Additional reported applications (for the relevant formats) include: immunoprecipitation and Western blotting. No. to) are specially developed and recommended. Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 2-6 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Reinheit: LEAF

Reinigung: The antibody was purified by affinity chromatography.

Buffer: Phosphate-buffered solution, pH 7.2, containing no preservative. 0.2 µm filter sterilized. Endotoxin level is < 0.1 EU/µg of the protein (< 0.01 ng/µg of the protein) as determined by the LAL test.

Lagerung: The antibody solution should be stored undiluted at 4° C. This LEAF(TM) solution contains no preservative, handle under aseptic conditions.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

anti-GM-CSF antibody

Publikationen

Publikationen: Mahanty, Abrams, King et al.: "Parallel regulation of IL-4 and IL-5 in human helminth infections." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 148, Issue 11, pp. 3567-71, 1992 (PubMed).

Abrams, Roncarolo, Yssel et al.: "Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples." in: Immunological reviews, Vol. 127, pp. Mai 24, 1992 (PubMed).

Negrin, Greenberg: "Therapy of hematopoietic disorders with recombinant colony-stimulating factors." in: Advances in pharmacology (San Diego, Calif.), Vol. 23, pp. 263-96, 1992 (PubMed).

Demetri, Griffin: "Granulocyte colony-stimulating factor and its receptor." in: Blood, Vol. 78, Issue 11, pp. 2791-808, 1991 (PubMed).

Fan, OBrian, Ioannides et al.: "Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer." in: In vivo (Athens, Greece), Vol. 5, Issue 6, pp. 571-7, 1992 (PubMed).

Kita, Ohnishi, Okubo et al.: "Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils." in: The Journal of experimental medicine, Vol. 174, Issue 3, pp. 745-8, 1991 (PubMed).

Bacchetta, de Waal Malefijt, Yssel et al.: "Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 144, Issue 3, pp. 902-8, 1990 (PubMed).